BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/13/2021 10:05:39 AM | Browse: 777 | Download: 1976
 |
Received |
|
2021-01-26 07:02 |
|
Peer-Review Started |
|
2021-01-26 07:09 |
|
First Decision by Editorial Office Director |
|
2021-02-27 18:03 |
|
Return for Revision |
|
2021-02-27 18:03 |
|
Revised |
|
2021-03-10 09:53 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2021-04-20 13:27 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2021-04-21 17:38 |
|
Articles in Press |
|
2021-04-21 17:38 |
|
Edit the Manuscript by Language Editor |
|
2021-05-07 02:04 |
|
Typeset the Manuscript |
|
2021-05-11 04:58 |
|
Publish the Manuscript Online |
|
2021-05-13 10:05 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yue Han, Wei-Hua Zhi, Fei Xu, Chen-Bo Zhang, Xiao-Qian Huang and Jian-Feng Luo |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Yue Han, PhD, Doctor, Doctor, Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 9 Dongdan 3rd Alley, Dongcheng, Beijing 100021, China. doctorhan@163.com |
| Key Words |
Hepatocellular carcinoma; Systemic therapy; Meta-analysis; Lenvatinib; First-line; Immune therapy |
| Core Tip |
The present network meta-analysis is the first to compare data from randomized trials of all first-line systemic therapies for hepatocellular carcinoma including chemotherapy, targeted drugs, immunotherapy and combination therapies. Furthermore, the analysis represents a comprehensive cross comparison of outcomes, including tumor response rates, survival, and safety and included a sub-analysis in patients with HBV infection. Our results showed that atezolizumab plus bevacizumab was ranked first for progression-free survival and overall survival but also had the highest rate of discontinuations due to adverse events. Lenvatinib ranked first for overall response rate and second for progression-free survival. |
| Publish Date |
2021-05-13 10:05 |
| Citation |
Han Y, Zhi WH, Xu F, Zhang CB, Huang XQ, Luo JF. Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. World J Gastroenterol 2021; 27(19): 2415-2433 |
| URL |
https://www.wjgnet.com/1007-9327/full/v27/i19/2415.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v27.i19.2415 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
